Detailed characterisation of non-bleeding visible vessels in terms of colour, size evolution, and time of rebleeding is important in determining the natural history of these lesions. The colour and size of non-bleeding visible vessels were observed endoscopically every day for three days and then every other day until rebleeding or flattening of visible vessels occurred in 140 patients. Rebleeding happened in 61 (44%) patients. Of them, 59 (97%) rebled within 72 hours. Flattening of visible vessels happened in 79 (56%) patients and 77 of 79 (98%) had flattening of visible vessels within 72 hours. Rebleeding rate increased with increasing length of exposed vessels (r=0.96, p<0001). Coffee ground fluid or blood retention in the stomach and ulcer size -2*0 cm were independent predictors for rebleeding using multivariate analysis. It is suggested that patients with non-bleeding visible vessels and independent predictors for rebleeding may need early aggressive treatnent.
Gastric fluid (clear, coffee ground or bloody) was recorded at endoscopy. Gentle washing technique was applied to remove blood and adherent clots to adequately observe the ulcer base. A visible vessel was defined as a discrete protuberance within the ulcer crater that had recently bled. The length of exposed NBVVs and peptic ulcers were measured by an endoscopic meter (Olympus M2-4K). We took at least six photographs for NBVVs at entry and in follow up endoscopies.
The patients' vital signs were checked every hour for 12 hours, every two hours for another 12 hours, every four hours for a subsequent 24 hours until they became stable, and then four times daily. Shock was defined as systolic pressure less than 100 mm Hg and a pulse rate greater than 100 bpm. The haemoglobin and packed cell volume values were checked every day, and a blood transfusion was given if the haemoglobin concentration dropped to less than 9 g/dl or if vital signs deteriorated. H2 Blockers (ranitidine 150 mg every 12 hours or cimetidine 300 mg every six hours intravenously) were given routinely during the stay in hospital.
A nasogastric tube was inserted and irrigated with water every two hours for every patient until occurrence of rebleeding or flattening of NBVVs. Endoscopy was performed every day for three days, then every other day until rebleeding or flattening of NBVVs occurred. If the NBVVs flattened, the patient was discharged and followed up at the outpatient department every week. An endoscopic examination was performed every month for three months. H2 Blockers (ranitidine 150 mg or cimetidine 400 mg twice daily) were given orally to every patient for at least two months at the outpatient department.
Rebleeding was suspected if a patient had fresh blood in the stomach six hours after entry to the study, presence of unstable vital signs, and continued tarry, bloody stools or haematemesis. We performed an emergency endoscopy for these patients. If alcohol injection, heater probe thermocoagulation) for those who experienced rebleeding. If patients refused endoscopic treatment, surgical intervention was conducted.
A positive history of non-steroid antiinflammatory drug (NSAID) ingestion was defined as >1 tablet/day NSAID ingestion within seven days of admission for peptic ulcer bleeding. Positive cigarette smoking was defined as 10 cigarettes per day for at least one year. Positive alcohol drinking was defined as :40 g/day alcohol consumption for at least six months.
Three groups of different severity of comorbid illness were classified as: group 1, no pre-existing illness; group 2, stable pre-existing illness (such as ischaemic heart disease, well controlled hypertension, diabetes mellitus, cardiac failure, cirrhosis of liver, cerebrovascular disease, chronic airway disease), or gastrointestinal bleeding after an uncomplicated procedure (such as cholecystectomy, repair of fracture); group 3, serious intercurrent illness (such as decompensated heart disease, decompensated liver disease, active malignancy, severe sepsis, dialysis dependent acute renal failure, multiple injuries) or gastrointestinal bleeding when acutely ill after a major operation (such as cardiac surgery or repair of aortic aneurysm). 23 We With regard to the colour of NBVVs at entry to the study, we found seven different colours (red, dark red, black, white, pink, grey, and brown) in the ulcer bases (Figs 1 and 2 ). Red and dark red NBVVs (78 of 145, 54%) were most commonly found, followed by black NBVVs (33 of 145, 23%), and white NBVVs (26 of 145, 18%) . The rebleeding rate was highest in the white colour NBVVs (15 of 26, 58%) followed by red (27 of 58, 47%), pink (2 of 5, 40%), black (13 of 33, 40%), dark red (6 of 20, 30%), brown (0 of 2), and grey NBVVs (0 of 1). No significant difference of rebleeding rates was found in the diverse colour NBVVs. There was no constant colour evolution for NBVVs in our series.
The length of the exposed NBVVs varied from one mm to seven mm. NBVVs of one mm and two mm length were most commonly found (102 of 145, 70%) (Figs 3 and 4) . Rebleeding rates for one mm, two mm, three mm, four mm, five mm, six mm, seven mm NBVVs were 34% (24 of 70), 44% (14 of 32), 52% (14 of 27), 60% (6 of 10), 67% (2 of 3), 100% (2 of 2), and 100% (1 of 1), respectively. The rebleeding rate increased with increasing length of exposed NBVVs (r=0.96, p<0-0001).
Forty eight of 61 rebleeders received endoscopic treatment (22: adrenaline injection, 22: adrenaline plus pure alcohol injection, and four: heater probe thermocoagulation), 11 received surgery, one received pitressin infusion, and one received medical treatment.
A total of 10 patients with NBVVs died in this series. One died of continuous bleeding before surgical intervention, and five rebleeding patients died of surgical complications (two complicated with respiratory failure, one with heart failure, and two with gall bladder gangrene). Four patients who had flattening of NBVVs died of unrelated illness (one cerebrovascular accident, one lymphoma, one respiratory failure, and one cachexia).
In non-rebleeders, 63 patients (72%) received an endoscopic follow up for at least two months. Fifty of them (79%) had scars at the previous ulcer location two months later. We could not follow up 43 of these patients for 18 (8) months (mean (SD)). A total of nine rebleeding episodes occurred in six patients during follow up. Eight rebleeding episodes subsided spontaneously. One rebleeding episode subsided after heater probe thermocoagulation.
Discussion
In recent years, attention has been paid to the finding of NBVVs in peptic ulcer (24) FRebled (23) L Flattened then rebled on day 8 (1)
Rebled (10) (2) Rebled (2) 7 mm (1) Rebled (1) Figure 4 : Size evolution of 63 visible vessels (61 patients) that rebled. Numbers in parentheses show numbers ofvisible vessels.
bases, because a life threatening haemorrhage originates from an eroded artery rather than a non-arterial bleeding, which will probably stop by itself.8 24 In our series, the likelihood of NBVVs in peptic ulcers rebleeding was 23% (140 of 604), which was comparable with other findings.5 9 25-27 Predicting rebleeding in peptic ulcers with NBVVs is no doubt important for clinicians because of a six to 12-fold increase in mortality in rebleeders.28-31 A combination of clinical and endoscopic risk factors can provide a more reliable prediction of rebleeding than individual criteria.' 19 20 For example, endoscopic stigmata associated with hypotension had a much higher rebleeding rate than that of stigmata without hypotension.7 32 Different timing of endoscopy has undoubtedly resulted in a diverse occurrence ofNBVVs in published reports. 6 25 We performed endoscopy within 24 hours in every case to avoid this problem. Also, to avoid interobserver variation, the findings of NBVVs were all confirmed by two experienced endoscopists.
A logical evolution of the colour of NBVVs of stigmata of haemorrhage with bleeding peptic ulcer has been proposed by Johnston.19 The arterial bleeding sequence is: a large red clot contiguous with a visible vessel develops, then a small red visible vessel, followed by a dark visible vessel, then a white visible vessel, and finally the clot disappears. In our series, the colour change of red visible vessels could be as many as six different colours on the next day if no rebleeding or flattening of visible vessels occurred. There was also no constant change for visible vessels of other colours. The hypothesis of red-black-white then disappearance of visible vessels should be revised.
The In conclusion, most rebleeding episodes or flattening of NBVVs occurred within 72 hours of observation. Their colour evolutions could be multifarious. The rebleeding rates increased with increasing length of the exposed NBVVs. With multivariate analysis, independent predictors for rebleeding at endoscopy were: coffee ground fluid or blood retention in the stomach, and an ulcer size :two cm. We suggest endoscopic haemostatic treatment or surgery for patients with NBVVs who have any of the above independent predictors.
